COVID-19 Screening in Rheumatologic Diseases Cases; Special Look at Chloroquine Derivate Use
نویسندگان
1 Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
2 Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
3 Department of Rheumatology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
4 Department of Rheumatology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
5 Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran
6 Shahid Beheshti University of Medical Sciences, Tehran, Iran
7 Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran
8 Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
9 Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
10 Exercise Physiology Research Center, Life Style Institute, Baqyiatallah University of Medical Sciences, Tehran, Iran
11 Sina Hospital, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran
12 Iran University of Medical Science, Tehran, Iran
13 Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran
14 Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran
doi
10.34172/hpr.2021.27چکیده
Background: Among suggested medications for the treatment of COVID-19, chloroquine derivates and angiotensin-converting–enzyme inhibitors (ACEIs)/angiotensin II type 1 receptor blockers (ARBs) are the two medications with conflicting effects on the development of the disease.Objectives: The present study aimed to evaluate COVID-19 in patients with rheumatic diseases receiving chloroquine derivate.Methods: Every patient with proven rheumatologic diseases registered in two referral centers in Tehran and Alborz, Iran was enrolled in the present descriptive cross-sectional study between May and June 2020. At first, the symptoms of COVID-19 were assessed, and if a case had suspicious symptoms, reverse transcription-polymerase chain reaction (RT-PCR) COVID-19 tests were done. Demographic and clinical data are documented for every patient. Then, the patients were grouped once according to their COVID-19 infection status and another time according to their hydroxychloroquine use.Results: 1159 patients enrolled in the study with a mean age of 49.39 years. Frequency of hypertension was 22.17 %, diabetics (9.49%) and 20 (1.7%) patients were positive for COVID-19 testing. The most common symptoms of the COVID-19 positive cases were cough (5.2%) and fever (4%). There was no significant difference in receiving ACEIs/ARBs or other medications between COVID-19 positive or negative patients. Among the patients receiving hydroxychloroquine, 15 patients (1.7%) had proved COVID-19 versus 5 patients (1.7%) who were not receiving these medications (P>0.999).Conclusion: The present study demonstrated that receiving ARBs or ACEIs was not different among patients with or without COVID-19. Moreover, receiving chloroquine derivate was not related to the development of COVID-19 in patients with rheumatologic disorders.
